Hepatic profile analyses of tipranavir in Phase II and III clinical trials

BACKGROUND: The risk and course of serum transaminase elevations (TEs) and clinical hepatic serious adverse event (SAE) development in ritonavir-boosted tipranavir (TPV/r) 500/200 mg BID recipients, who also received additional combination antiretroviral treatment agents in clinical trials (TPV/r-ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Mikl, Jaromir, Sulkowski, Mark S, Benhamou, Yves, Dieterich, Douglas, Pol, Stanislas, Rockstroh, Jürgen, Robinson, Patrick A, Ranga, Mithun, Stern, Jerry O
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803791/
https://www.ncbi.nlm.nih.gov/pubmed/20003457
http://dx.doi.org/10.1186/1471-2334-9-203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803791/
https://www.ncbi.nlm.nih.gov/pubmed/20003457
http://dx.doi.org/10.1186/1471-2334-9-203

Ejemplares similares